Quinoline-imidazole/benzimidazole derivatives as dual-/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 10 2022
Historique:
received: 05 05 2022
accepted: 27 09 2022
entrez: 10 10 2022
pubmed: 11 10 2022
medline: 13 10 2022
Statut: epublish

Résumé

Two new classes of hybrid quinoline-imidazole/benzimidazole derivatives (the hybrid QIBS salts and QIBC cycloadducts) were designed and synthesized to evaluate their anticancer and antimicrobial activity. The strategy adopted for synthesis is straight and efficient, in four steps: N-acylation, N-alkylation, quaternization and a Huisgen 3 + 2 cycloaddition. The in vitro single-dose anticancer assay of forty six hybrid quinoline-benzimidazole compounds reveal that one QIBS salt (11h), has an excellent quasi nonselective activity against all type of cancer cell with an excellent PGI in the area of 90-100% and very good lethality. Three others quinoline-imidazole/benzimidazole hybrids (8h, 12h, 12f) has an excellent selective activity against some cancer cell lines: breast cancer MDA-MB-468 and Leukemia HL-60 TB). The five-dose assay screening confirms that compound 11h possesses excellent anti-proliferative activity, with GI

Identifiants

pubmed: 36216981
doi: 10.1038/s41598-022-21435-6
pii: 10.1038/s41598-022-21435-6
pmc: PMC9551061
doi:

Substances chimiques

14-alpha Demethylase Inhibitors 0
Anti-Bacterial Agents 0
Antifungal Agents 0
Antineoplastic Agents 0
Benzimidazoles 0
Dermatologic Agents 0
Gentamicins 0
Imidazoles 0
Quinolines 0
Salts 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16988

Informations de copyright

© 2022. The Author(s).

Références

Eur J Med Chem. 2017 Jan 27;126:705-753
pubmed: 27951484
Eur J Med Chem. 2020 Oct 15;204:112651
pubmed: 32738414
Eur J Med Chem. 2014 Apr 9;76:31-42
pubmed: 24565571
J Med Chem. 2014 Dec 26;57(24):10257-74
pubmed: 25255204
Antimicrob Agents Chemother. 2013 Jun;57(6):2838-40
pubmed: 23507273
Future Med Chem. 2020 Feb;12(3):207-222
pubmed: 31916456
Molecules. 2020 Jun 26;25(12):
pubmed: 32604828
Eur J Med Chem. 2018 Jan 1;143:1277-1300
pubmed: 29126724
J Infect Public Health. 2017 Jul - Aug;10(4):369-378
pubmed: 27616769
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30397070
Eur J Med Chem. 2019 Apr 1;167:133-145
pubmed: 30771601
Eur J Med Chem. 2017 Oct 20;139:22-47
pubmed: 28800458
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
RSC Adv. 2021 Nov 29;11(60):38297-38301
pubmed: 35498117
Tuberculosis (Edinb). 2014 Jul;94(4):357-62
pubmed: 24841672
Bioorg Med Chem. 2021 Feb 15;32:115973
pubmed: 33444846
J Enzyme Inhib Med Chem. 2016;31(sup2):96-103
pubmed: 27250919
Eur J Med Chem. 2014 Apr 9;76:494-505
pubmed: 24602792
Curr Med Chem. 2020;27(1):154-169
pubmed: 30569842
Eur J Med Chem. 2019 Mar 1;165:59-79
pubmed: 30660827
Eur J Med Chem. 2019 Jul 15;174:1-8
pubmed: 31015103
Curr Med Chem. 2007;14(13):1459-77
pubmed: 17584056
Eur J Med Chem. 2021 Aug 5;220:113555
pubmed: 34052677
Eur J Med Chem. 2017 Jan 5;125:143-189
pubmed: 27662031
Eur J Med Chem. 2014 Apr 9;76:549-57
pubmed: 24607998
Crit Rev Microbiol. 2016 Aug;42(4):594-606
pubmed: 25383647
J Pharm Anal. 2016 Apr;6(2):71-79
pubmed: 29403965
Nat Rev Cancer. 2006 Oct;6(10):813-23
pubmed: 16990858
Ann Clin Microbiol Antimicrob. 2012 Jun 20;11:18
pubmed: 22716026
Eur J Med Chem. 2014 Apr 22;77:422-87
pubmed: 24685980
Bioorg Med Chem. 2008 Sep 15;16(18):8587-91
pubmed: 18752962
Pharmaceuticals (Basel). 2021 Apr 06;14(4):
pubmed: 33917439
Curr Drug Discov Technol. 2020;17(5):574-584
pubmed: 30894111

Auteurs

Dumitrela Diaconu (D)

Institute of Interdisciplinary Research, Department of Exact and Natural Sciences - CERNESIM Centre, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania.

Vasilichia Antoci (V)

Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania.

Violeta Mangalagiu (V)

Institute of Interdisciplinary Research, Department of Exact and Natural Sciences - CERNESIM Centre, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania.

Dorina Amariucai-Mantu (D)

Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania. dorina.mantu@uaic.ro.

Ionel I Mangalagiu (II)

Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania. ionelm@uaic.ro.
Institute of Interdisciplinary Research, Department of Exact and Natural Sciences - CERNESIM Centre, Alexandru Ioan Cuza University of Iasi, 11 Carol I, 700506, Iasi, Romania. ionelm@uaic.ro.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH